Skip to main content

Executive Team

Meet the Innovators Behind CluePoints’ Success

Discover what it's like to work at CluePoints

Introducing

our team, each a master of their respective craft.

Andy Cooper

Chief Executive Officer

Andy holds a degree in Pharmacology from the University of Leeds, UK, where his final year was focused on data mining the human genome for undiscovered inwardly rectifying potassium channels. This ignited Andy’s passion for applying software to address data challenges in drug development. Andy has spent the past 20+ years working at software companies to provide solutions that enable global Clinical Operations, Clinical Data Management, and Pharmacovigilance business processes. Andy joined CluePoints in December 2022 and serves as the Chief Executive Officer.
Patrick Hughes

Co-Founder & Chief Commercial Officer

Patrick holds a Marketing degree from the University of Newcastle-upon-Tyne, UK, and a post-graduate Marketing diploma in Business-to-Business Marketing Strategy from Northwestern University - Kellogg School of Management, Chicago, Illinois. Responsible for leading global sales, product, marketing, operational, and technical teams throughout his career, Patrick is a Senior Executive with over 25 years of international commercial experience within life sciences, healthcare, and telecommunications. In the past, Patrick consulted on corporate and commercial strategy for various life sciences companies. In addition, he was responsible for successfully positioning ClinPhone as the leading Clinical Technology Organization during his 10-year tenure with the company.
Francois Torche

Chief Product & Technology Officer & Co-Founder

François holds a Master's in Business Administration from the ICHEC School of Management, Brussels, Belgium. Throughout his career in the pharmaceutical industry, he has held positions as a statistical programmer, SAS and JAVA developer, and IT project leader for companies such as GSK, UCB, and IDDI. During his ten-year tenure with IDDI as an IT Specialist, Mr. Torche assisted in the development of the SMART™ engine, a patent-pending software solution, and the underpinning of CluePoints. Francois served as CluePoints’ Chief Executive Officer since the company’s inception in 2012 until December 2022. More recently, he now holds the position of Chief Product & Technology Officer & Co-Founder.
Steve Young

Chief Scientific Officer

As Chief Scientific Officer for CluePoints, Steve oversees the research and development of advanced methods for data analytics, data surveillance, and risk management, along with guiding customers in RBQM methodology and best practices. Steve worked for three biopharmaceutical companies over 15 years, where he assumed leadership positions in clinical data management and led the successful enterprise roll-out of EDC at both J&J and Centocor. He spent an additional six years with eClinical solution providers Medidata and OmniComm, leading the development of analytics and risk-based quality management (RBQM) solutions and providing RBQM consultation to many organizations. Steve also led a pivotal RBM-related analysis in collaboration with TransCelerate and is currently leading RBQM best-practice initiatives for several industry RBM consortiums. Steve holds a Master’s degree in Mathematics from Villanova University.
Adrien Lebrun

Senior Vice President, Product

Adrien holds three master's degrees in Political Science, European Politics, and Management from the University of Brussels. He has more than 15 years of experience in the technology and software industry, focusing on complex and regulated environments (Pharmaceuticals, Banking, and Telco). For the past years, he has mainly focused on helping B2B SaaS startups with their scale-up and growth by designing, building, and leading successful product and technology teams. He is a fervent lean methodology advocate who loves working in a fast-paced agile environment.
Holly Gratkowski, PhD

Chief Operations Officer

Holly is responsible for CluePoints Operational Team that focuses on delivering CluePoints solutions to our Pharmaceutical, Biotechnology, and CRO clients. She has over 20 years of experience in the Pharmaceutical Industry and has been with CluePoints since 2019. Before her current position, she spent nine years with Signant Health (formerly Bracket) in various roles concentrating on leading operational teams and overseeing strategic account delivery. She also held positions at Amicus Therapeutics and IBM Global Business Services in Healthcare and Life Sciences. She is passionate about coaching and developing high-performing teams, especially within clinical development and data management. Holly received a Ph.D., MS, and BA from the University of Pennsylvania in Biochemistry. She and her husband are raising three wonderful boys and live in the Western suburbs of Philadelphia, Pennsylvania.
Amit Patel

Chief Financial Officer

Amit holds a Banking & International Finance degree from Cass Business School in London. In his early career, he spent several years working in investment banking and private equity in London before founding his own payment technology business, which he scaled and sold to a US competitor. Since then and for the past ten years, Amit has worked as CFO to several private equity-backed high-growth SaaS companies. He has been involved in the entire business life-cycle, from start-up to growth equity fundraising to strategic exit. Amit joined CluePoints in February 2023 as Chief Financial Officer.
Céline Daubresse

Chief People Officer

Céline is a highly experienced Chief People Officer, holding a degree in Work and Social Psychology from the University of Louvain-la-Neuve in Belgium. In addition, with 20 years of experience in Human Resources Management, she is deeply passionate about supporting leadership teams in creating a work environment and a company culture that inspires and empowers people to achieve their full potential and drive overall success.
Marc Buyse, ScD

Founder

Marc Buyse holds degrees from Brussels University (Belgium), Cranfield University (UK), and a ScD in biostatistics from the Harvard School of Public Health (USA). Before founding the International Drug Development Institute (IDDI) in 1991, he had worked at the European Organization for Research and Treatment of Cancer (EORTC) in Brussels and the Dana Farber Cancer Institute in Boston. He is also the founder of CluePoints, a company dedicated to the statistical monitoring of clinical trials, and an Associate Professor of Biostatistics at the Limburgs Universitair Centrum, Diepenbeek, Belgium. Marc works primarily on statistical methods for personalized medicine. (http://publicationslist.org/marc.buyse).

We've Got News!

Visit our Newsroom for our latest news.

Featured Whitepaper

ICH E6 (R2)
Summary
Paper

Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.

Learn More

Featured Webinar

ICH E6 (R2)
Webinar
Series

This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.

Learn More

We're Kind of a Big Deal.

7,000

Platform Users

1,200

Studies De-Risked

100,000

Issues Detected